The Clinical Presentation of Culture-positive and Culture-negative, Quantitative Polymerase Chain Reaction (qPCR)-Attributable Shigellosis in the Global Enteric Multicenter Study and Derivation of a Shigella Severity Score: Implications for Pediatric Shigella Vaccine Trials.
Patricia B PavlinacJames A Platts-MillsKirkby D TickellJie LiuJane JumaFurqan KabirJoseph NkezeCatherine OkoiDarwin J OperarioJashim UddinShahnawaz AhmedPedro L AlonsoMartin AntonioStephen M BeckerRobert F BreimanAbu S G FaruqueBarry FieldsJean GratzRashidul HaqueAnowar HossainM Jahangir HossainSheikh JarjuFarah QamarNajeeha Talat IqbalBrenda KwambanaInacio MandomandoTimothy L McMurryCaroline OchiengJohn B OchiengMelvin OchiengClayton OnyangoSandra PanchalingamAdil KalamFatima AzizShahida QureshiThandavarayan RamamurthyJames H RobertsDebasish SahaSamba O SowSuzanne E StroupDipika SurBoubou TambouraMami TaniuchiSharon M TennantAnna RooseDeanna ToemaYukun WuAnita ZaidiJames P NataroMyron M LevineEric R HouptKaren L KotloffPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
A composite severity score consistent with severe disease or dysentery may be a pragmatic clinical endpoint for severe shigellosis in vaccine trials. Reliance on culture for microbiologic confirmation may miss a substantial number of Shigella cases but is currently required to measure serotype specific immunity.